Current Knowledge of Beta-Blockers in Chronic Hemodialysis Patients
Int J Nephrol Renovasc Dis. 2023 Oct 12;16:223-230. doi: 10.2147/IJNRD.S414774. eCollection 2023.ABSTRACTBeta-blockers include a large spectrum of drugs with various specific characteristics, and a well-known cardioprotective efficacy. They are recommended in heart failure, hypertension and arrhythmia. Their use in chronic hemodialysis patients is still controversial, mainly because of the lack of specific randomized clinical trials. Large observational studies and two important clinical trials have reported almost unanimously their efficacy in chronic hemodialysis patients, which seems to be related to their levels of dia...
Source: International Journal of Nephrology and Renovascular Disease - October 18, 2023 Category: Urology & Nephrology Authors: Intissar Haddiya Siria Valoti Source Type: research